

6th November, 2020

To
The General Manager,
Department of Corporate Relations,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Dear Sir,

Scrip Code: 536565

**Sub: Outcome of Board Meeting dated 6th November, 2020 and Disclosure as per Regulation 30 of
SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

We wish to inform you that at the meeting of the Board of Directors of the Company held today i.e. on Friday, 6th November, 2020, the Board of Directors of the Company have inter-alia considered, approved the following:

1. Took on record the unaudited standalone and consolidated financial results of the Company for the quarter ended 30th September, 2020. The said unaudited financial results were reviewed by the Audit Committee and thereafter approved by the Board of Directors.

The Statutory Auditors have carried out a "Limited Review" of the unaudited Financial Results for the quarter ended 30th September, 2020.

2. In continuation to our letter vide dated 29th July, 2020, this is to inform that the Company has received food license and has started sales of drug, food and ayurvedic products.

In compliance with Regulations 33 & Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a copy of the Standalone and Consolidated Financial Results and Limited Review Report of the Statutory Auditors of the Company.

The Board Meeting commenced at 03:00 p.m. and concluded at 05:00 p.m.

This is for your information and records.

Thanking you.
Yours faithfully,

For Trimurthi Limited

(Arun Kumar Bhagatia)
Managing Director
DIN: 00021024



Encl: As Above

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/A&C, Inderbagh, Sultanbazar,
Hyderabad - 500 075, T.S. INDIA. | Tel: 040 24757370
Email: info@trimurthidrugs.com
Website: www.trimurthidrugs.com
CIN No: L67120TG1994PLC018956



P. MURALI & CO.,

CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

Independent Auditor's Review Report on the Quarterly Unaudited Ind AS Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors
Trimurthi Limited:

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of M/s TRIMURTHI LIMITED ("the Company") for the quarter and half year ended September 30, 2020 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019
2. The preparation of "the Statement", which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We have conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.





P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

4. Based on our review conducted, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.
Chartered Accountants
FRN: 007257S



A. Krishna Rao

Partner
M.No. 020085
UDIN: 20020085AAAATI6097

Place: Hyderabad
Date: 06-11-2020

TRIMURTHI LIMITED
4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad - 500095.
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS
FOR THE QUARTER II AND HALF YEAR ENDED 30TH SEPTEMBER 2020

(Amount in Indian rupees (Rs))

PARTICULARS	QUARTER ENDED		HALF YEAR ENDED		YEAR ENDED 30.9.2020 (AUDITED)
	30.9.2020 (UNAUDITED)	30.9.2020 (UNAUDITED)	30.9.2019 (UNAUDITED)	30.9.2020 (UNAUDITED)	
1. INCOME					
INCOME FROM OPERATIONS	30.21	24.72	34.79	34.31	33.86
OTHER INCOME	6.40	11.22	8.24	17.42	23.00
TOTAL INCOME	36.61	35.94	33.03	51.73	56.86
2. EXPENSES					
PURCHASE	28.72	28.47	18.37	27.15	30.47
COST OF MATERIALS CONSUMED			—		
MANUFACTURING EXPENSES			—		
WORK IN PROGRESS AND STOCK IN TRADE	0.17	0.40	1.12	(2.29)	(0.35)
RENT	0.40	0.23	0.05	0.00	0.00
EMPLOYEE BENEFITS EXPENSE	0.72	0.28	7.75	(5.88)	(2.94)
FINANCE COSTS	—	—	—	—	—
DEPRECIATION AND AMORTISATION EXPENSES	2.14	2.18	1.97	4.32	8.04
OTHER EXPENSES	5.43	6.71	4.35	31.14	13.22
TOTAL EXPENSES	43.18	41.80	34.76	44.79	66.43
ITEMS (1-2)	(6.57)	(5.86)	(11.73)	(13.06)	(5.57)
3. EXCEPTIONAL ITEMS/ PRIOR PERIOD ITEMS					
3. PROFIT/LOSS FROM ORDINARY ACTIVITIES BEFORE TAX (3-4)	(8.57)	(5.48)	(11.40)	(13.06)	(7.58)
4. TAX EXPENSES					
-CURRENT TAX	—	—	0.30	—	—
TAX ADJUSTMENTS RELATING TO EARLIER YEARS			—		
DEFERRED TAX (NET)	0.00	0.07	0.00	0.00	0.00
5. NET PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (3-4)	(8.57)	(6.41)	(10.34)	(12.06)	(7.58)
6. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS					
6A. TAX EXPENSES FOR DISCONTINUED OPERATIONS					
6B. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS (AFTER TAX) (6-7)					
7. PROFIT/(LOSS) FOR THE PERIOD (5+6)	(8.57)	(6.41)	(10.34)	(12.06)	(7.58)
8. OTHER COMPREHENSIVE INCOME					
8A. (i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS					
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS					
8B. (i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS					
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS					
9. TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (5+6+7+8)	(8.57)	(6.41)	(10.34)	(12.06)	(7.58)
10. (i) EARNINGS PER EQUITY SHARE (FOR CONTINUING OPERATIONS):					
(i) BASIC	0.00	0.00	0.00	0.00	0.00
(ii) DILUTED	(0.00)	(0.00)	(0.15)	(0.16)	(0.16)
11. EARNINGS PER EQUITY SHARE (FOR DISCONTINUING OPERATIONS):					
(i) BASIC	0.00	0.00	0.00	0.00	0.00
(ii) DILUTED	0.00	0.00	0.00	0.00	0.00
12. EARNINGS PER EQUITY SHARE (FOR CONTINUING AND DISCONTINUING OPERATIONS):					
(i) BASIC	0.00	0.00	0.00	0.00	0.00
(ii) DILUTED	(0.00)	(0.00)	(0.15)	(0.16)	(0.16)

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email: info@trimurthiindia.com
Website: www.trimurthiindia.com
CIN No: L67120TG1994PLC018956



TRIMURTHI LIMITED
SCHEDULE II OF THE COMPANIES ACT 2013
PART-II



PARTICULARS	QUARTER ENDED			Half Year Ended		YEAR ENDED
	30.09.2020 (UNAUDITED)	30.06.2020 (UNAUDITED)	30.09.2019 (UNAUDITED)	30.09.2020 (UNAUDITED)	30.06.2019 (UNAUDITED)	31.03.2020 (AUDITED)
PART II CLASS OF SHARE HOLDING						
A. Public Share Holding						
i. Number of Shares	2900000	2900000	2900000	2900000	2900000	2900000
Percentage of shareholding	35.81%	35.81%	35.81%	35.81%	35.81%	35.81%
Promoters and promoter group shareholding						
ii. Promoter & its associates						
- No. of Equity Shares	-	-	-	-	-	-
- Percentage of Shares or the shareholding of promoter and promoter group	-	-	-	-	-	-
- Percentage of Shares of the total share capital of the company	-	-	-	-	-	-
iii. Non-promoter						
- No. of Equity Shares	2199400	2199400	2199400	2199400	2199400	2199400
- Percentage of Shares or the shareholding of promoter and promoter group	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares or the total share capital of the company	84.19%	84.19%	84.19%	84.19%	84.19%	84.19%
iv. Participants						
v. Investor Complaints						
vi. Floating at the beginning of the quarter	-	-	-	-	-	-
Received during the quarter	-	-	-	-	-	-
Repaid during the quarter	-	-	-	-	-	-
Remaining received during the quarter	-	-	-	-	-	-

TRIMURTHI LIMITED

Segment Reporting

PARTICULARS	QUARTER ENDED			Half Year Ended		YEAR ENDED
	30.09.2020 (UNAUDITED)	30.06.2020 (UNAUDITED)	30.09.2019 (UNAUDITED)	30.09.2020 (UNAUDITED)	30.06.2019 (UNAUDITED)	31.03.2020 (AUDITED)
Segment Revenue						
i. a. Pharma Business	-	-	-	-	-	-
b. Financial Services	5.44	7.41	8.21	12.48	21.69	42.36
c. Investments	0.96	3.78	0.06	4.76	3.95	6.51
d. Trading in Shares	30.21	24.10	14.73	54.31	33.86	107.47
e. Foods	-	-	-	-	-	-
	36.67	36.04	23.00	71.97	56.86	150.34
Total	36.67	36.04	23.00	71.97	56.86	150.34
Less: Inter Segment Revenue	36.67	36.04	23.00	71.97	56.86	150.34
Net Segment Profit (Before tax & Interest From Each Segment)						
i. a. Pharma Business	-	-	-	-	-	-
b. Financial Services	5.44	7.41	8.21	12.48	21.69	42.36
c. Investments	0.96	3.78	0.06	4.76	3.95	6.51
d. Trading in Shares	(12.47)	(17.70)	(26.77)	(76.47)	(32.56)	(156.44)
e. Foods	-	-	-	-	-	-
	(6.57)	(8.46)	(18.79)	(113.96)	(27.56)	(106.08)
Total	(6.57)	(8.46)	(18.79)	(113.96)	(27.56)	(106.08)
Less: Interest	-	-	-	-	-	-
i. Other Unallocable expenses net off	-	-	-	-	-	-
ii. Unallocable Income	-	-	-	-	-	-
	16.57	18.46	(18.79)	(113.96)	(27.56)	(106.08)
Total Profit Before Tax						
i. a. Pharma Business	29.50	29.50	-	29.50	-	29.50
b. Financial Services	543.89	247.39	546.22	349.82	560.22	567.96
c. Investments	29.82	13.64	29.00	29.82	29.00	29.18
d. Trading in Shares	485.11	700.49	375.71	487.11	375.79	486.44
e. Foods	500.00	300.00	12.34	300.00	12.34	300.00
	1,194.29	1,200.69	1,192.19	1,194.29	1,192.19	1,207.46

The format for the Audited quarterly results as prescribed in SEBI Circular CIR/CFD/CMD/15/2013 dated November 30, 2013 has been modified to comply with the requirements of SEBI Circular CIR/CFS/FAC/16/2016 dated July 5, 2016.

1. Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.

2. The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors of the Company held on 06-11-2020.

3. The above standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS-14-Indian Financial Reporting Standards as prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.

Page 10 of 10
Dated
06-11-2020

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)

4-4-231/1/2/ABC, Inderbagh, Sultanbazar

Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370

Email : info@trimurthi drugs.com

Website : www.trimurthi drugs.com

CIN No : L67120TG1994PLC018956



TRIMURTHI LIMITED
Standalone Statement of Assets and Liabilities



Particulars	(Amount in Lakhs)	
	Half Year Ended 30-09-2020	Year Ended 31-03-2020
ASSETS		
1 Non Current Assets		
a Property, Plant and Equipment	26.57	30.82
b Capital Work in Progress	-	-
c Investment Property	-	-
d Goodwill	-	-
e Other intangible Assets	0.01	0.08
f Intangible Assets under development	-	-
g Biological assets other than bearer plants	-	-
h Financial Assets:		
Investments	159.12	352.68
Trade Receivables	-	-
Loans	-	-
Others	-	-
Loans	-	-
Others	-	-
i Deferred Tax Assets (net)	-	-
Other Non Current Assets	20.00	20.00
Total Non Current Assets	405.98	403.58
2 Current Assets		
a Inventories	10.05	7.83
b Financial Assets:		
Investments	-	-
Trade Receivables	7.90	228.32
Cash and Cash Equivalents	180.08	45.23
Bank balances other than above	-	-
Loans	349.85	367.98
Others	-	-
c Current Tax Assets (net)	-	-
d Other Current Assets	238.64	101.05
Total Current Assets	786.53	800.40
Total Assets	1,192.42	1,203.98
EQUITY AND LIABILITIES		
1 Equity		
a Equity- Share Capital	810.00	810.00
b Other Equity	384.28	397.10
Total - Equity	1,194.28	1,207.10
2 Liabilities		
Non Current Liabilities		
a Financial Liabilities:		
Borrowings	-	-
Trade Payables	-	-
Other Financial Liabilities	-	-
b Provisions	-	-
c Deferred Tax Liabilities (net)	(5.98)	(5.85)
d Other Non Current Liabilities	-	-
Total Non Current Liabilities	(5.98)	(5.85)
Current Liabilities		
a Financial Liabilities:		
Borrowings	-	-
Trade Payables	2.55	0.67
Other Financial Liabilities	-	-
b Other Current Liabilities	1.29	1.42
c Provisions	-	-
d Current Tax Liabilities (net)	-	0.64
Total Current Liabilities	4.12	2.73
Total - Equity and Liabilities	1,192.42	1,203.98

TRIMURTHI LIMITED

Plot Hyderabad (Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
Date: 06-11-2020
#4-231 /1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email: info@trimurthidrugs.com
Website: www.trimurthidrugs.com
CIN No: L47120TG1994PLCD18956

For Trimurthi Ltd
Arun Kumar Bhagadia
Managing Director
Din No: 00021024



TRIMURTHI LIMITED
 4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad-500095.

STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 30TH SEPT, 2020

Particulars	(Rs. In Lakhs)	
	As at 30.09.2020	As at 31.03.2020
A. Cash Flow from Operating Activities:		
Net Profit before Tax and Extraordinary Items	(13.06)	10.65
Adjustments for:		
Depreciation	4.32	7.82
Interest & Other Income	(11.58)	(38.98)
Profit/Loss on Sale of Investments & Property	(4.74)	(4.53)
Operating profit before Working Capital Changes	(25.05)	(25.03)
Adjustments for:		
Trade and Other receivables	100.96	159.33
Inventories	(2.23)	3.19
Trade payables	2.03	(11.88)
Cash generated from Operations	100.76	150.64
Cash flow before Extraordinary Items	75.71	125.61
Extraordinary Items and Tax	(0.64)	(4.49)
Net Cash used for Operating activities	75.07	121.13
B. Cash Flow from Investing Activities:		
Purchase of Fixed Assets	0.00	(1.49)
Sale of Fixed Assets	0.00	0.00
Capital Work in progress	0.00	0.00
Purchase /Sale of Investments	(1.79)	(79.42)
Increase / (Decrease) in Security Deposits	0.00	0.00
Interest & Other Income	11.58	38.98
Net Cash flow from Investing activities	9.78	(41.93)
C. Cash Flow from Financing Activities:		
Increase in Share Capital	0.00	0.00
Increase in Share Premium	0.00	0.00
Increase / Decrease in Long Term Borrowings	0.00	0.00
Share Issue and Preliminary Expenses	0.00	0.00
Dividends Paid	0.00	0.00
Net Cash flow from Financing activities	0.00	0.00
Net Increase in Cash and Cash Equivalents	84.85	79.19
Cash and Cash Equivalents as at (Opening Balance)	95.23	16.03
Cash and Cash Equivalents as at (Closing Balance)	180.08	95.23

For Trimurthi Limited

Place: Hyderabad

Date: 06-11-2020

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
 4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
 Hyderabad - 500 095, T.S. INDIA. | Tel: 040-24757370
 Email : info@trimurthidrugs.com
 Website : www.trimurthidrugs.com
 CIN No : L67120TG1994PLC018956

 Arun Kumar Bhangadia
 Managing Director
 DIN No. 00021024




Independent Auditor's Review Report on the Quarterly Unaudited Ind AS Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The board of directors
Trimurthi Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of TRIMURTHI LIMITED(the "Holding Company") and its subsidiaries(the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended Sep 30, 2020 and for the period from 01-04-2020 to 30-09-2020 ("the Statement"), being submitted by the "Holding Company" pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on "the Statement" based on our review

We conducted our review of "the Statement" in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether "the Statement" is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

"The Statement" includes the Ind AS financial results of the following entities:

- a) Trimurthi Foods
- b) Trimurthi Pharmaceuticals (India) Private Limited

Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.
Chartered Accountants
FRN: 007257S


A. Krishna Rao
Partner
M.No. 020085
UDIN: 20020085AAAATJ6878



Place: Hyderabad
Date: 06-11-2020.

TRIMURTHI LIMITED
SCHEDULE III OF THE COMPANIES ACT 2013
CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2020

(Amount in Lakhs Except EPS)

PART-I

Particulars	Quarter Ended			Half Year Ended		Year Ended 31/03/2020
	30/09/2020	30/06/2020	30/09/2019	30/09/2020	30/09/2019	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
I. Income From Operations						
Net Sales / Income from Operations	248.47	205.47	262.26	453.94	505.94	1024.44
Other Income	6.54	11.21	20.18	18.36	24.43	60.11
II. Total Income	255.01	217.28	282.44	472.30	530.37	1084.55
III. Expenses						
a. Consumption of Raw Material	56.22	40.09	55.58	102.31	67.06	211.84
b. Purchase of Traded Goods/Shares	125.64	101.80	154.47	217.43	292.33	532.33
c. (Increase) / Decrease in stock in trade and work in Progress	3.64	(0.54)	(0.16)	5.11	(0.25)	19.45
d. Manufacturing Expenses	45.17	37.31	44.39	83.08	103.62	162.05
e. Employee benefits expense	20.60	22.57	26.24	51.15	48.40	96.40
f. Rent	1.60	1.40	1.50	3.00	3.00	6.75
g. Finance Cost	2.08	2.20	2.67	4.32	6.37	11.45
h. Depreciation	2.50	4.95	4.73	7.45	10.40	19.14
i. Other Expenditure	10.26	10.78	10.78	21.04	25.36	55.12
Total	267.69	227.20	300.13	494.89	586.43	1356.04
IV. Profit/(Loss) before Exceptional and Tax (II-III)	(12.68)	19.92	(17.69)	(22.60)	(14.06)	(21.80)
V. Exceptional Items/Prior Period Items						
VI. Profit/(Loss) before Tax (IV-V)	(12.68)	19.92	(17.69)	(22.60)	(14.06)	(21.80)
VII. Tax expense						
(i) Current tax	3.54	3.90	(0.50)	1.38	2.15	4.41
(ii) Deferred tax	1.28	0.00	(0.94)	3.24	1.21	2.74
VIII. Net Profit/(Loss) for the period from continuing operations (VI-VII)	(15.22)	18.95	(17.19)	(24.18)	(18.22)	(25.91)
IX. Profit/(Loss) from discontinued operations	NIL	NIL	NIL	NIL	NIL	NIL
X. Tax expenses of discontinued operations	NIL	NIL	NIL	NIL	NIL	NIL
XI. Profit/(Loss) from Discontinued operations (after tax) (IX-X)	NIL	NIL	NIL	NIL	NIL	NIL
XII. Profit/(Loss) for the period (VIII+XI)	(15.22)	18.95	(17.19)	(24.18)	(18.22)	(25.91)
XIII. Other Comprehensive Income						
A. (i) Items that will not be reclassified to profit or loss	0.00	0.11	0.67	0.11	(1.25)	(3.45)
(i) Income tax relating to items that will not be reclassified to profit or loss	NIL	NIL	NIL	NIL	NIL	NIL
(ii) Items that will be reclassified to profit or loss	NIL	NIL	NIL	NIL	NIL	NIL
(ii) Income tax relating to items that will be reclassified to profit or loss	NIL	NIL	NIL	NIL	NIL	NIL
Total Comprehensive Income for the period (XII+XIII) Comprising Profit (Loss) and Other comprehensive income for the period	(15.22)	18.95	(16.32)	(24.07)	(18.45)	(28.34)
XIV. Minority Interest	1.45	0.34	0.10	1.21	1.22	2.43
XV. Total Comprehensive Income for the period after Minority Interest (XIV-XV)	(16.87)	18.61	(16.62)	(25.38)	(20.67)	(31.76)
XVI. Earnings per equity share (for continuing operations)						
(1) Basic	(0.21)	0.11	(0.28)	(0.31)	(0.24)	0.35
(2) Diluted	(0.21)	0.11	(0.21)	(0.31)	(0.24)	0.35
XVII. Earnings per equity share (for discontinuing operations)						
(1) Basic	NIL	NIL	NIL	NIL	NIL	NIL
(2) Diluted	NIL	NIL	NIL	NIL	NIL	NIL
XVIII. Earnings per equity share (for discontinuing & continuing operations)						
(1) Basic	(0.21)	(0.11)	(0.21)	(0.31)	(0.24)	0.35
(2) Diluted	(0.21)	(0.11)	(0.21)	(0.31)	(0.24)	0.35

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/A8C, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956



TRIMURTHI LIMITED

SCHEDULE III OF THE COMPANIES ACT 2013

PART-II

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30/09/2020	30/06/2020	30/09/2019	30/09/2020	30/06/2019	31/03/2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
A. Particulars Of Share Holding						
1. Public Share Holding						
- Number of Shares	2900600	2900600	2900600	2900600	2900600	2900600
- Percentage of shareholding	35.81%	35.81%	35.81%	35.81%	35.81%	35.81%
2. Promoter and promoter group shareholding						
a. Pledged / encumbered						
- No of Equity Shares	-NIL-	-NIL-	-NIL-	-NIL-	-NIL-	-NIL-
- Percentage of Shares (of the shareholding of promoter and promoter group)	-NIL-	-NIL-	-NIL-	-NIL-	-NIL-	-NIL-
	- NIL-	- NIL-	- NIL-	- NIL-	- NIL-	- NIL-
	- Percentage of Shares (of the total share capital of the company)	- NIL-	- NIL-	- NIL-	- NIL-	- NIL-
b. Not encumbered						
- No of Equity Shares	5199400	5199400	5199400	5199400	5199400	5199400
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- 100.00%	- 100.00%	- 100.00%	- 100.00%	- 100.00%	- 100.00%
	- Percentage of Shares (of the total share capital of the company)	64.19%	64.19%	64.19%	64.19%	64.19%
B. Investor Complaints						
Outstanding at the beginning of the quarter	-NIL-	-	-	-	-	-
Received during the quarter	-NIL-	-	-	-	-	-
Disposed during the quarter	-NIL-	-	-	-	-	-
Remaining unsolved during the quarter	-NIL-	-	-	-	-	-

Segment Reporting

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30/09/2020	30/06/2020	30/09/2019	30/09/2020	30/06/2019	31/03/2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Segment Revenue						
a. Pharma Business	110.58	83.59	148.86	194.17	279.86	531.77
b. Financial Services	5.48	6.04	7.39	13.51	20.27	47.79
c. Investments	0.96	3.78	(0.07)	4.74	5.78	4.33
d. Foods	107.79	87.78	131.09	265.37	192.25	393.96
e. Trading in Shares	30.21	24.10	15.08	34.31	34.21	101.45
Total	255.08	217.28	282.84	472.30	530.37	1064.55
Less: Inter Segment Revenue	-NIL-	-NIL-	0.00	-NIL-	-	-NIL-
Net Sales/ Income From Operations	255.08	217.28	282.84	472.30	530.37	1064.55
2. Segment Profit (Before tax & Interest From Each Segment)						
a. Pharma Business	6.05	(1.07)	0.34	4.18	8.34	6.39
b. Financial Services	3.41	9.78	14.09	9.19	20.27	36.28
c. Investments	0.96	3.78	(0.07)	4.74	5.78	4.33
d. Foods	(10.15)	0.31	1.12	(9.93)	(12.22)	(32.36)
e. Trading in Shares	(12.97)	(17.70)	(25.97)	(30.87)	(32.23)	(60.44)
Total	(32.66)	(9.92)	(17.69)	(22.60)	(16.08)	(21.50)
Less:						
i. Interest	-NIL-	-NIL-	-NIL-	-NIL-	-NIL-	-NIL-
ii. Other Un-allocable expenses net off	-NIL-	-NIL-	-NIL-	-NIL-	-NIL-	-NIL-
iii. Un-allocable income	-NIL-	-NIL-	-NIL-	-NIL-	-NIL-	-NIL-
Total Profit Before Tax	(12.66)	(9.92)	(17.69)	(22.60)	(16.08)	(21.50)
3. Capital Employed						
a. Pharma Business	77.27	74.89	84.70	79.37	84.70	75.38
b. Financial Services	349.05	267.00	449.46	549.85	649.46	367.98
c. Investments	29.82	13.61	37.14	29.82	37.14	23.48
d. Foods	62.87	105.60	189.06	92.87	189.06	107.31
e. Trading in Shares	485.11	590.68	913.01	485.11	913.01	486.44
Total	1224.52	1051.79	1071.38	1034.92	1071.38	1060.29

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)

4-4-231/1/2/ABC, Inderbagh, Sultnabazar

Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370

Email : info@trimurthidrugs.com

Website : www.trimurthidrugs.com

CIN No : L67120TG1994PLC018956





TRIMURTHI
GROUP

1. Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 06-11-2020.
3. The Standalone Unaudited Financial Results have been prepared and subjected to Limited Review by the Statutory Auditor in accordance with Indian Accounting Standards (Ind-AS) as notified by Ministry of Corporate Affairs, Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III, Division II of Companies Act, 2013. The Limited Review was carried out by Statutory Auditors for the Quarter and half year ended 30th September, 2020. The Ind-AS Compliant figures for the Corresponding previous Quarter ended 31st March, 2019 have not been subject to review or audit, however the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
4. The results are also available on the website of the Company.

Place : Hyderabad

Date : 06-11-2020



TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,

Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370

Email : info@trimurthidrugs.com

Website : www.trimurthidrugs.com

CIN No : L67120TG1994PLC018956



TRIMURTHI LIMITED
Consolidated Statement of Assets and Liabilities



TRIMURTHI
GROUP

	Particulars	Half Year Ended 31-09-2020	Year Ended 31-03-2021	(Amount in Lakhs)
ASSETS				
1 Non Current Assets				
a Property, Plant and Equipments		173.50	177.69	
b Capital Work In Progress		-	-	
c Investment Property		-	-	
d Goodwill		-	-	
e Other Intangible Assets		4.95	5.50	
f Intangible Assets under development		-	-	
g Biological assets other than inventories		-	-	
h Financial Assets:				
Investments		36.30	29.66	
Trade Receivable		-	-	
Loans		-	-	
Others		-	-	
Loans		-	-	
Others		-	-	
i Deferred Tax Assets (net)		-	-	
Other Non Current Assets		20.08	20.15	
	Total Non Current Assets	234.83	233.00	
2 Current Assets				
a Inventories		92.61	90.66	
b Financial Assets:				
Investments		-	-	
Trade Receivables		137.25	161.34	
Cash and Cash Equivalents		346.42	311.78	
Bank Balances other than above		-	-	
Loans		281.85	445.00	
Others		277.21	145.40	
c Current Tax Assets (net)		-	-	
d Other Current Assets		-	-	
	Total Current Assets	1,113.34	1,139.21	
	Total Assets	1,350.17	1,372.21	
EQUITY AND LIABILITIES				
1 Equity				
a Equity Share Capital		810.00	810.00	
b Other Equity		234.92	250.29	
Total - Equity		1,034.92	1,060.29	
Non Controlling Interest		53.78	52.48	
2 Liabilities				
Non Current Liabilities				
a Financial Liabilities		-	-	
Borrowings		66.64	76.72	
Trade Payables		-	-	
Other Financial Liabilities		-	-	
b Provisions		-	-	
c Deferred Tax Liabilities (net)		2.28	1.90	
d Other Non Current Liabilities		-	-	
	Total Non Current Liabilities	70.88	78.62	
Current Liabilities				
a Financial Liabilities				
Borrowings		-	-	
Trade Payables		156.68	164.83	
Other Financial Liabilities		-	-	
b Other Current Liabilities		30.67	13.28	
c Provisions		-	-	
d Current Tax Liabilities (net)		1.24	2.71	
	Total Current Liabilities	190.59	189.82	
	Total - Equity and Liabilities	1,350.17	1,372.21	

Page 11 of TRIMURTHI LIMITED

Date: 06-10-2020
Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email: info@trimurthidrugs.com
Website: www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

For Trimurthi Ltd
Arun Kumar Bhargava
Managing Director
Din No. 00021024



TRIMURTHI LIMITED

4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad-500095.

CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 30TH SEPT, 2020

TRIMURTHI
GROUP

(Rs. In Lakhs)

Particulars	As at 30.09.2020	As at 31.03.2019
A. Cash Flow from Operating Activities:		
Net Profit before Tax and Extraordinary Items	(22.60)	(21.50)
Adjustments for:		
Depreciation	7.45	19.14
Interest & Other Expense	4.32	11.45
Interest & Other Income	(12.98)	(46.14)
Miscellaneous Exp Write off	0.08	0.15
(Profit)/Loss on Sale of Assets		
(Profit)/Loss on Sale of Investments	(4.74)	(4.53)
Operating profit before Working Capital Changes	(28.46)	(41.43)
Adjustments for:		
Trade and Other receivables	260.43	36.00
Inventories	(1.92)	(11.29)
Trade payables	11.26	89.98
Cash generated from Operations	269.77	114.69
Cash flow before Extraordinary Items	241.31	73.26
Extraordinary Items and Tax	(2.74)	(10.51)
Net Cash used for Operating activities	238.57	62.76
B. Cash Flow from Investing Activities:		
Purchase of Fixed Assets	(2.72)	(10.58)
Sale of Fixed Assets	0.00	0.00
Capital Work in progress	0.00	0.00
Purchase/Sale of Investments	(1.79)	20.58
Increase / (Decrease) in Deposits	0.00	0.75
Interest & Other Income	8.66	34.69
Net Cash flow from Investing activities	4.14	45.45
C. Cash Flow from Financing Activities:		
Increase in Share Capital	-Nil-	-Nil-
Increase in Share Premium	-Nil-	-Nil-
Increase / Decrease in Long Term Borrowings	(8.08)	(16.35)
Share Issue and Preliminary Expenses	-Nil-	-Nil-
Dividends Paid	-Nil-	-Nil-
Capital Contribution from Minority Interest	-Nil-	-Nil-
Net Cash flow from Financing activities	(8.08)	(16.35)
Net Increase in Cash and Cash Equivalents	234.64	91.85
Cash and Cash Equivalents as at (Opening Balance)	111.78	19.93
Cash and Cash Equivalents as at (Closing Balance)	346.42	111.78

For Trimurthi Limited

Arun Kumar Bhangadia
Arun Kumar Bhangadia
Managing Director
DIN No. 00021024



TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA | Tel: 040 24757370
Email: info@trimurthidrugs.com
Website: www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956